AC
CRL icon

AlphaCore Capital’s Charles River Laboratories CRL Stock Holding History

AlphaCore Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
1,608
+11
+0.7% +$1.96K 0.01% 828
2026
Q1 		$275K Buy
1,597
+342
+27% +$63.4K 0.01% 713
2025
Q4 		$250K Buy
+1,255
New +$228K 0.01% 888

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

AlphaCore Capital's CRL Position: Q2 2026 in Review

AlphaCore Capital increased its Charles River Laboratories (CRL) stake by 0.69% in Q2 2026, buying an estimated $1.96K and bringing the position to 1,608 shares worth $365K. The position accounts for 0.01% of the portfolio, ranked #828.

AlphaCore Capital first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • AlphaCore Capital held 1,608 shares of Charles River Laboratories worth $365K as of Q2 2026.
  • AlphaCore Capital bought 11 Charles River Laboratories shares in Q2 2026, an estimated $1.96K.
  • Charles River Laboratories made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #828 holding.
  • AlphaCore Capital first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.